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Abstract
Background: Synovial Sarcomas (SS) are rare tumors occurring predominantly in adolescent and young adults with
a dismal prognosis in advanced phases. We report a first-in-human phase I of monoclonal antibody (OTSA-101) targeting
FZD10, overexpressed in most SS but not present in normal tissues, labelled with radioisotopes and used as a molecular
vehicle to specifically deliver radiation to FZD10 expressing SS lesions.
Methods: Patients with progressive advanced SS were included. In the first step of this trial, OTSA-101 in vivo bio-
distribution and lesions uptake were evaluated by repeated whole body planar and SPECT-CT scintigraphies from H1
till H144 after IV injection of 187 MBq of 111In-OTSA-101. A 2D dosimetry study also evaluated the liver absorbed dose
when using 90Y-OTSA-101. In the second step, those patients with significant tumor uptake were randomized between
370 MBq (Arm A) and 1110 MBq (Arm B) of 90Y-OTSA-101 for radionuclide therapy.
Results: From January 2012 to June 2015, 20 pts. (median age 43 years [21–67]) with advanced SS were enrolled. Even
though 111In-OTSA-101 liver uptake appeared to be intense, estimated absorbed liver dose was less than 20 Gy for
each patient. Tracer intensity was greater than mediastinum in 10 patients consistent with sufficient tumor uptake to
proceed to treatment with 90Y-OTSA-101: 8 were randomized (Arm A: 3 patients and Arm B: 5 patients) and 2 were not
randomized due to worsening PS. The most common Grade≥ 3 AEs were reversible hematological disorders, which
were more frequent in Arm B. No objective response was observed. Best response was stable disease in 3/8 patients
lasting up to 21 weeks for 1 patient.
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Conclusions: Radioimmunotherapy targeting FZD10 is feasible in SS patients as all patients presented at least one
lesion with 111In-OTSA-101 uptake. Tumor uptake was heterogeneous but sufficient to select 50% of pts. for 90Y-OTSA-
101 treatment. The recommended activity for further clinical investigations is 1110 MBq of 90Y-OTSA-101. However,
because of hematological toxicity, less energetic particle emitter radioisopotes such as Lutetium 177 may be a better
option to wider the therapeutic index.
Trial registration: The study was registered on the NCT01469975 website with a registration code NCT01469975 on
November the third, 2011.
Keywords: Synovial sarcoma, Radioimmunotherapy, Theranostic, First-in-human trial
Background
Synovial Sarcomas (SS) account for 2.5–5% of all soft
tissue sarcoma and affect all ages, but is most prevalent
among adolescents and young adults (15–40 years of
age) [1]. Therapy for patients with localized disease is
based on surgery followed by external radiotherapy.
Five-year overall survival rates range from 36 to 76%.
Recurrences may be local (30–50%) or distant (40%),
with lung being the most common site of distant metas-
tases. Survival is better in children, possibly because of
major biological differences between SS of adults and
children [2]. In the setting of advanced disease, systemic
chemotherapy with doxorubicin and/or ifosfamide is the
standard of care. However, median overall survival be-
comes close to 12–18 months [3, 4]. Most targeted
agents have failed to show significant activity except the
VEGFR inhibitors [5], pazopanib [6], and more recently
regorafenib [7]. Thus, therapeutic options in advanced
SS remain an unmet clinical need.
In a study by Nagayama et al., 26 genes were found to
be commonly upregulated in SS based on the
genome-wide gene expression profiles of 13 SS cases by
cDNA microarray, including Frizzled homologue 10
(FZD10) [8]. FZD10 belongs to the Frizzled family of
seven-pass transmembrane receptors for molecules in
the Wnt signaling pathway. It was found to be overex-
pressed in SS samples and was almost absent in
remaining normal adult tissues except the placenta [9].
Based on these findings, a specific monoclonal-antibody
that targets the N-terminal extracellular domain of
FZD10 (MAb 92–13) was developed as a first step
toward the development of an antibody-based therapy
for SS [10]. In vitro, MAb 92–13 has only a weak
antagonistic activity on cell growth and no/little
antibodydependent cellmediated cytotoxicity and
complement-dependent cytotoxicity. In vivo, when radi-
olabelled with Indium-111 (111In), it bound and accumu-
lated in up to 5 days after IV injection in SS tumor cells
overexpressing FZD10 (SYO-1) implanted in nude mice
and not in FZD10 negative SS tumor cells (LoVo). This
provided evidence for a specific binding. MAb 92–13
was proved to get internalized into tumor cells by
confocal microscopy and flow cytometric (FACS) analyses.
When it was radiolabeled with Yttrium-90 (90Y), a highly
energetic beta emitter radioisotope, tumor shrinkage was
observed in immunocompromised Balb-c mice bearing
established FZD10-positive SS tumor subcutaneous xeno-
grafts (SYO-1 cell line), without significant toxicity [10].
Indeed, tumor volumes were markedly reduced immedi-
ately after treatment after a single administration of
3,7 MBq. Median time to tumor progression was 58 days
in treated mice and 9 days in the control group.
All together, these preclinical data support the clinical
development of an antibody targeting FZD10 as a spe-
cific tool for radionuclide delivery to synovial sarcoma
cells. OTS has developed a radioimmunoconjugate
humanized anti-FZD10 Ab (OTSA-101) demonstrating
high in vitro affinity for FZD10.
In the present report, we describe the results of a FIH,
first in class phase I study evaluating the use of
111In-OTSA-101 and 90Y-OTSA-101 in patients with ad-
vanced synovial sarcoma following a theranostic approach.
Methods
Study population
Patients were required to have metastatic, histologically
confirmed, synovial sarcoma, resistant to standard treat-
ment, not amenable to therapy with curative intent (sur-
gery or radiotherapy) and previously treated with
doxorubicin and ifosfamide. Other key inclusion criteria
were: measurable disease as per Response Evaluation
Criteria in Solid Tumors version 1.1 (RECIST v1.1);
Eastern Cooperative Oncology Group Performance Sta-
tus (ECOG PS) ≤ 2, life expectancy ≥3 months, adequate
organ function, left ventricular ejection fraction > 50%;
normal pulmonary function with Force Vital Capacity
(FVC) at least 60% and diffusing capacity or transfer fac-
tor of the lung for carbon monoxide (DLCO) of at least
50%, no positive human anti-mouse antibody (HAMA)
or human anti-chimeric antibody (HACA) response.
Study drug
Oncology Therapy Science (OTS) provided a humanized
chimeric anti-FZD10 antibody (named OTSA-101)
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covalently bound to the chelating agent p-SCN-
Bn-CHX-A”-DTPA at molecular ratio varying between
2.0 and 3.6 (i.e. number of DTPA molecules to one mol-
ecule of antibody). The thiocyanate (SCN) group of the
linker reacts with the amino group of lysine of
OTSA-101 and is able to chelate radionuclides with five
carboxyl groups.
OTSA-101-DTPA was radiolabeled with Indium 111
(111In-OTSA-101- Step 1 Imaging part) or Yttrium 90
(90Y-OTSA-101- Step 2 Therapeutic Part). 275 MBq of
high purity 111In-chloride (specific activity >185GBq/g
indium) in diluted hydrochloric acid (Covidien, Petten,
The Netherlands) or 370 MBq or 1665 MBq of
90Ychloride (IBA-Cis bio, Saclay, France) were added to
1.5 mg of OTSA-101-DTPA in the presence of sodium
acetate buffer (0.2 M, pH 5) and was incubated 90 min
at 37 °C. At the end of the labeling, 0.8 mg of
EDTA-2Na were added in the mixture solution. The
radiochemical purity (RCP) was assayed with a gamma
isotope TLC analyzer (Raytest, Courbevoie, France)
using ITLC-SG (Biodex Tec-control black, Biodex, NY,
USA) and 0.9% sodium chloride solution as mobile
phase. 111In-OTSA-101 or 90Y-OTSA-101 remained at
the origin whereas unbound 111In migrated with an Rf of
0.9–1. The radiochemical purity (RCP) of radiolabeled
OTSA-101-DTPA was required to be over 90% before
injection.
OTSA-101 radiolabeled antibody was injected over a
30 min intravenous injection with follow-up of vital
signs (blood pressure, pulse rate and temperature) every
15 min until the end of infusion, and 1, 2, 3, 5 and 8 h
post-dose.
Study design
This trial was an open-label, single center FIH, in Class
Phase I study. The main aims were to evaluate the in
vivo tumor binding 111In-OTSA-101 and the feasibility
of a theranostic approach.
The design of the study was based on a theranostic ap-
proach. Indeed, this trial was divided in 2 steps: i) Dur-
ing the first step, called imaging part, patients received a
single IV injection of 111In-OTSA-101- and the in vivo
biodistribution of 111In-OTSA-101 was assessed using
planar whole body and thorax-abdomen-pelvis hybrid
Single Photon Emission Computed Tomography/Com-
puted Tomography (SPECT-CT) acquisitions (Tandem
Discovery NM/CT 670 from GE Medical Systems Ge
DISCOVERY NM/CT 670) performed at 1, 5, 24, 48, 72,
144 h post-injection. Indium 111 is a Gamma emitter
with a long physical half-life (67.4 h) allowing for re-
peated scintigraphies over few days to better assess
OTSA-101 lesions radiotracer kinetic. 111In-OTSA-101
tumor uptake compared to normal tissues uptake were
first assessed with a visual analysis using a 5 grades
visual scale applied on SPECT-CT images: grade 0, no
uptake; grade 1: less than background (mostly mediasti-
num); grade 2: equal to background; grade 3: greater
than background but less than liver; grade 4: equal or
greater than liver. A Steering Committee evaluated on a
case by case basis for each patient if he/she can proceed
to the therapeutic part based on tumor uptake grade:
patients were deemed eligible for the 2nd step only if
they had at least one tumor lesion demonstrating tracer
uptake greater than mediastinum (i.e. Grade > 2, Fig. 1)
and 2D estimated liver dose less than 20 Gy [11]. Indeed,
liver demonstrated the highest tracer uptake as usually
observed in radioimmunotherapy. In addition, patients
displaying abnormal/unexpected biodistribution of
111In-OTSA-101, or demonstrating with safety concerns
including abnormal bronchoscopy and/or clinical deteri-
oration due to rapid disease progression were withdrawn
from the study for other therapeutic plan; ii) During the
2nd step, called therapeutic part, 12 patients were to be
randomized between two initial dose levels of 90Y: Arm
A: 370 MBq versus Arm B: 1110 MBq. Then, based on
safety and preliminary efficacy data, a third dose level
was planned in 6 additional patients to be treated with
2220 MBq of 90Y-OTSA-101 (Arm C). The initial inter-
val between the 2 parts of the trial was 28 days, but was
reduced to 14 days considering the almost complete
clearance (less than 50 ng/mL) of the antibody from the
blood by day 14 after the infusion of 111In-OTSA-101.
Of note, during the course of the study a protocol
amendment was made to close the Arm A due to no
clinical benefit observed in the first 3 patients and Arm
C was never opened.
Finally, patients who achieved at least stable disease
following 12 weeks of treatment were allowed to receive
additional doses of 90Y-OTSA-101 (according to the ran-
domisation arm) with a maximum of 4 doses per year.
Clinical assessments
The clinical assessments included complete medical his-
tory, physical examination, ECOG PS, triplicate 12-lead
ECGs, tumor imaging and standard laboratory assess-
ments. Additional investigation included respiratory
function tests (including CO diffusion assessment) and
cardiac assessments. A bronchoscopy was added to the
screening due to occurrence of hemoptysis and follow-
ing the recommendations of iDMC. Toxicity was evalu-
ated on clinical examination and laboratory assessments
performed 1, 2, 4, 6, 12 weeks after the injection and
every 3 months thereafter. All AE were graded according
to the National Cancer Institute-Common Terminology
Criteria (NCI-CTCAE) Tumor assessments were done at
baseline, at weeks 6 and 12 and every 3 months
thereafter. Tumor response was evaluated as per
RECIST v1.1.
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Pharmacokinetic sampling (PK)
In the first step, blood sample collection for PK analysis
was performed at 1, 5, 24, 48, 72, 144 h post-dosing with
additional sampling at 7 days after the injection. In the
2nd step, PK sampling for OTSA-101 was performed 1,
5, 24, 48 h after the injection with additional sampling at
14 and 28 days after the infusion and during the end of
study visit. In addition, blood sample collection for ADA
was done for all patients at pre-dose and 7 days after in-
jection during the first step and at pre-dose and 14,
28 days after the injection in the second step. All PK
and ADA samples were analyzed by Altanbio (Nantes,
France). The analytical method consists of Ligand
Binding Assay (LBA) that used biotinylated anti-idiotypic
OTSA-101 for capture and the same anti-idiotypic
antibody conjugated to sulfo-TAG for detection. The Soft-
maxPro v5.4 Molecular device software was used for
regression, calculation of concentration and the Watson
LIMS 7.2 software for pharmacokinetic calculation.
Statistics
The sample size was set to screen patients for major tox-
icity occurring in a large portion of the target popula-
tion. Especially, based on binomial probabilities, in 6
patients treated with a specific dose of 90Y-OTSA-101
there was a 90% probability of observing one or more
patients with a toxicity event, if that event occurs in at
least 32% of the target population. Cohorts of 6 patients
were to be initially randomized to the first 2 doses of
90Y-OTSA-101 (370 or 1110 MBq of 90Y). Then, a 3rd
dose level of 90Y was planned to be investigated. The
total number of treated patients was expected to be 18,
depending of the number of Limiting Event (Imaging
Part) and the number of Severe Toxicity (Therapeutic)
occurring.
The primary endpoint for imaging part (part 1) was
the rate of Limiting Event defined as unacceptable/unex-
pected biodistribution of OTSA-101 and/or absence of
tumor uptake. Secondary endpoints were to describe the
PK and safety profile of 111In-OTSA-101. The primary
endpoint for Part 2 was the rate of severe toxicities
defined any of the following AE assessed as related to
the study drug and graded according to National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) v4.0 criteria: i) Grade 4
hematological toxicity lasting more than 7 days; ii)
Grade 3 hematological toxicity lasting more than
2 weeks; iii) Any clinical (i.e. non-laboratory related tox-
icity) non-hematological Grade 3, iv) Any persistent
Grade 2 toxicity on end organs (liver, kidneys, lung,
Fig. 1 Consort diagram
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heart…). The secondary endpoints were the rate of ob-
jective response as per RECIST v1.1, the clinical benefit
rate and duration of response as well as PK parameters.
The safety population consists of all patients who re-
ceived OTSA-101 and the intent-to-treat population
consists of all included patients. Due to the nature and
design of the study, the statistical analysis had mainly
descriptive. Categorical data were described using con-
tingency tables with frequencies and percentages. The
missing data were not taken into account in percentages.
Quantitative data were presented using number of
observations, mean, standard deviation, median, max-
imum and minimum values. The statistical software
SAS® release 9.4 was used for the analyses.
Results
Patient characteristics and consort diagram
From January 2012 to June 2015, 20 patients with ad-
vanced/recurrent synovial sarcoma were enrolled in the
Imaging part (See Fig. 1 and Table 1). Among them, 10
had insufficient tumor uptake making them ineligible for
Part 2 and 10 patients have shown significant tumor up-
take of whom: i) 8 patients were randomized in the
Therapeutic part (3 patients in Arm A (370 MBq of 90Y)
and 5 patients in Arm B (1110 MBq of 90Y)) and ii) 2
patients were not randomized and not treated with
90Y-OTSA-101 due to rapid general health status deteri-
oration leading to early deaths (Fig. 1).
Their clinical characteristics are described in Table 1.
Briefly, there was an equal number of female and male,
their median age was 43.0 years (min-max: 21–67). The
most common histological subtype was spindle cell SS
(14/20 patients (74%)) and SYT-SSX1 the most common
Table 1 Patients characteristics at baseline
Imaging Part Therapeutic Part
N = 20 N = 8
N (%) Arm A Arm B
N N
Number of Patients 20 3 5
Sex
Men 10 (50.0%) 2 3
Women 10 (50.0%) 1 2
Age at inclusion (years)
Mean 42.1 31.0 41.4
SD 13.68 10.44 13.59
Median 43.0 26.0 43.0
Range 21–67 24–43 21–57
PS (ECOG)
0 8 (40.0%) 1 2
1 10 (50.0%) 2 2
2 2 (10.0%) 0 1
Primary tumor sites
(at initial diagnosis)
Upper limb 1 (5.0%) 0 1
Lower limb 8 (40.0%) 2 2
Trunck wall 5 (25.0%) 0 2
Internal trunck 4 (20.0%) 0 0
Head and neck 2 (10.0%) 1 0
Histological type
Missing 1 0 1
Spindle cell 14 (73.7%) 3 2
Biphasic 2 (10.5%) 0 1
Poorly differentiated 3 (15.8%) 0 1
Histological grade
at initial diagnosis
Grade 2 7 (35.0%) 3 2
Grade 3 13 (65.0%) 0 3
T T1 5 (25.0%) 0 2
T2 14 (70.0%) 3 3
TX 1 (5.0%) 0 0
N N0 19 (95.0%) 3 5
N1 1 (5.0%) 0 0
M M0 20 (100%) 3 5
Tumor depth
Superficial 3 (15.0%) 1 2
Deep 17 (85.0%) 2 3
Disease status at inclusion
Metastatic 18 (90.0%) 3 4
Locally advanced 1 (5.0%) 0 1
Both 1 (5.0%) 0 0
Surgery of the primary tumor
Yes 18 (90%) 3 4
Table 1 Patients characteristics at baseline (Continued)
Imaging Part Therapeutic Part
N = 20 N = 8
N (%) Arm A Arm B
N N
No 2 (10%) 0 1
Prior Radiotherapy
Yes 15 (75.0%) 3 3
No 5 (25.0%) 0 2
Chemotherapy with Doxorubicin
Yes, in monotherapy 5 (25.0%) 1 2
Yes, associated 15 (75.0%) 2 3
Chromosomal translocation site
missing 1 0 0
SSX1 11 (57.9%) 1 4
SSX2 5 (26.3%) 1 0
Others 3 (15.8%) 1 1
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molecular variant (11/20 (58%)). Almost all patients (19/20
patients) had metastatic disease at study entry, and lung
was the most common site of metastasis. All patients had
received prior chemotherapy with doxorubicin and the
median number of previous regimen.
Imaging studies, biodistribution and 2D dosimetry
All patients underwent at least 4 time points planar and
SPECT-CT acquisitions. Planar and SPECT-CT images
demonstrated physiological radiotracer accumulation
predominantly in the liver, and at lower level in the
blood pool, spleen, kidneys and intestines, and a very
low bone marrow uptake. 111In-OTSA-101 lesions up-
take was observed in all patients (at least Grade 1) with
heterogeneous intensity on an inter-patient based ana-
lysis. Figure 2 shows examples of the highest radiotracer
uptake in 3 patients on whole body planar acquisition
(Fig. 2a) and on the correspondent SPECT-CT acquisi-
tion (Fig. 2b). Patients 3 and 8 demonstrated the most
intense lesions uptake. Figure 3 shows the repeated plen-
ary whole body scans for patient 8. Lung lesions uptake
visually increased in time compare to mediastinal blood
pool activity, consistent with specific tumor binding and
internalization of the radiolabeled antibody.
Tracer uptake became greater than mediastinum in at
least one lesion for 9 patients (grade 3 or 4) as soon as
1 h after 111In-OTSA-101 injection for 2 patients and
became obvious only at the last point acquisition for 3
patients. Some patients demonstrated large volume tu-
mors with highly heterogeneous uptake consistent with
tumor necrosis on CT (patients 12, 14 and 15). Tumor
uptake was not correlated to tumor size and varied from
one lesion to another in the same patient (Table 2). For
example, patient 3 demonstrated a grade 2 in a 41 mm
lesion in the right lung (Fig. 4a) as well as a grade 4 in a
40 mm left lung lesion (Fig. 4b).
Two-D dosimetry in the liver lead to a mean of 2.15 Gy
[1.90–2.56 Gy] for the 3 patients in Arm A and 7.21 Gy
[5.43–10.57 Gy] for the 5 patients in Arm B. Liver dose es-
timation was never to be greater than 20 Gy.
Overall, 10 patients were assessed as candidates to
randomisation by the Steering committee including 9
a
b
Fig. 2 111In-OTSA-101 visual uptake grading. Examples of 111In-OTSA-101 tumors uptake visualized in 3 patients on planar imaging (a) and
assessed using visual scale applied on SPECT-CT acquisitions (b)
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patients with at least one lesion with tumor uptake ≥
Grade 3 and 1 patient with Grade 2 (Patient 2, first pa-
tient randomized).
Safety
During the Imaging part, 19 of 20 patients (95%) experi-
enced at least one adverse event (AE), 32 events were re-
ported and 16 of 20 patients (80%) experienced at least 1
related AE. The most frequent related AEs (≥10%) were
hypophosphatemia, lymphopenia, anemia, creatinine in-
creased, hypomagnesemia, hemoptysis and leucopenia.
The most frequent NCI CTCAE AE (≥10%) was lympho-
penia. Of note only 1 patient experienced at least one re-
lated AE Grade ≥ 3: a Grade 3 lymphopenia. Thirteen
SAEs were reported during the imaging part, all consid-
ered unrelated to study drug. No significant weight loss,
deterioration of ECOG performance status, electrocardio-
gram changes were observed during the imaging part.
During the Therapeutic part, a total of 8 patients were
randomized: 3 first patients received a single dose of
370 MBq of 90Y-OTSA-101, 4 patients received a single
injection of 1110 MBq of 90Y-OTSA-101 and 1 patient
received 2 injections of 1110 MBq of 90Y-OTSA-101
(Patient 01–003 who presented a SD at week12 was
injected a second time at week 24). All patients
experienced at least one AE in both study arms with a
total of 90 related AEs (Table 3). Treatment-related AEs
Grade ≥ 3 were seen in 4/5 patients in Arm B and 1/3
patients in Arm A. The most common related AEs were
hematological toxicity (i.e. anemia, lymphopenia,
Fig. 3 111In-OTSA-101 whole body planar scintigraphy repeated over time for patient 8 showing increasing lesions uptake compare to
mediastinal blood pool
Table 2 Minimal and maximal grade of 111In-OTSA-101 uptake
in all the lesions for each patient. Only lesions greater than
1 cm were analyzed
Pt Grade min Grade max
pt 1 0 2
pt 2 0 2
pt 3 1 4
pt 4 1 1
pt 5 4 4
pt 6 0 2
pt 7 1 1
pt 8 2 4
pt 9 1 1
pt 10 1 3
pt 11 1 3
pt 12 4 4
pt 13 2 2
pt 14 3 3
pt 15 3 3
pt 16 1 1
pt 17 1 1
pt 18 1 1
pt 19 1 1
pt 20 2 4
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thrombocytopenia, and neutropenia). Six SAEs were
considered related to study drug during the therapeutic
part, including one Suspected Unexpected Serious
Adverse Reaction (SUSAR). Only one System Class
Organ was represented: « Blood and lymphatic system
disorders » with four cases of reversible lymphopenia
and one case of thrombocytopenia. The reported SUSAR
was a case of “Massive Hemoptysis leading to death”
occurred in a 50 year-old female patient (Patient 3)
1.5 month after the 2nd injection of 90Y-OTSA-101 in a
context thrombocytopenia (61,000 / mm3) and progres-
sive lung metastases responsible of alveolar hemorrhage.
The thrombocytopenia was probably related to the study
drug, hemoptysis probably related to both study drug (as
a complication of thrombocytopenia) and medical
context of SS with progressive lung metastases.
Tumor response
Tumor response was evaluated in the Therapeutic part
(n = 8) at W6, W12 then every 12 weeks until EOS and
assessed as per RECIST 1.1. No objective response was
observed. The best overall response was SD in 3 patients
(Table 4). Time to disease progression is summarised on
Fig. 5. At Week 12, one patient (Patient 01–003) was
assessed as SD in Arm B and received a 2nd injection of
90Y-OTSA-101 performed 6 months apart. This 49-year
female patient remained progression-free for up to
21.4 weeks but died from haemoptysis related to lung
disease progression.
Pharmacokinetic & ADA
All patients, but one, had negative immunogenicity re-
sults (data not shown). The mean antibody serum
half-lives were respectively 265.7 h (SD: 316.9; %CV:
119.3) in the first step, and 87.4 (SD: 66.6; %CV: 76.2) in
Fig. 4 111In-OTSA-101 SPECT-CT images performed at H72 in patient
3 showing a grade 2 lesion in the right lower lung lobe (a) and a
grade 4 lesion in the left lower lung lobe (b)
Table 3 Treatment-related adverse events (AEs) observed
during the therapeutic Part
Arm A - 370 MBq Arm B - 1110 MBq
N = 3 N = 5
Patients Patients
N % N %
All treatment-related AEs 3 (100.0%) 4 (80.0%)
Lymphopenia 3 (100.0%) 4 (80.0%)
Anemia 3 (100.0%) 3 (60.0%)
Leucopenia 1 (33.3%) 4 (80.0%)
Asthenia 2 (66.7%) 2 (40.0%)
Hemoptysis 1 (33.3%) 3 (60.0%)
Thrombopenia 1 (33.3%) 3 (60.0%)
Neutropenia 0 (0.0%) 3 (60.0%)
Anorexia 2 (66.7%) 0 (0.0%)
Creatinine increased 0 (0.0%) 2 (40.0%)
Hypokalemia 1 (33.3%) 1 (20.0%)
Nausea 1 (33.3%) 1 (20.0%)
Hypoalbuminemia 1 (33.3%) 0 (0.0%)
Hypophosphatemia 0 (0.0%) 1 (20.0%)
Hypoxemia 0 (0.0%) 1 (20.0%)
Vomiting 1 (33.3%) 0 (0.0%)
Weight loss 1 (33.3%) 0 (0.0%)
All treatment-related
AE≥ Grade 3
1 (33.3%) 4 (80.0%)
Lymphopenia 0 (0.0%) 3 (60.0%)
Thrombopenia 1 (33.3%) 2 (40.0%)
Anemia 1 (33.3%) 1 (20.0%)
Neutropenia 0 (0.0%) 2 (40.0%)
Asthenia 1 (33.3%) 0 (0.0%)
Hemoptysis 0 (0.0%) 1 (20.0%)
Hypoxemia 0 (0.0%) 1 (20.0%)
Leucopenia 0 (0.0%) 1 (20.0%)
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Arm A and 61.8 (SD: 29; %CV: 46.9) in Arm B in the
second step (S3) (Table 5). This led to a significantly re-
duced radiopharmaceutic exposure in the therapeutic
part versus the imaging part.
Discussion
We reported results of a FIH study with a
radio-immuno-conjugate targeting FZD10 in patients
with advanced synovial sarcoma. The concept of
vectorising cytotoxic and radionuclide has emerged
20 years ago when the first monoclonal antibodies as
anti-cancer agents where approved, with some successes
like radiolabelled anti-CD20 (Zevalin®) applied to
non-Hodgkin-lymphoma as reviewed by Rizzieri [12] or
more recently radiolabelled anti-PSMA applied to
metastatic prostate cancer [13]. The overall aim of these
anti-body drug conjugates (ADC) and radio-immunotherapy
(RIT) is to use the specificity of monoclonal antibodies for
their target to deliver a highly toxic payload (cytotoxic
drug or radionuclide) to tumor cells, thus avoiding sys-
temic toxicity of this payload. Key aspects in developing
ADC/RIT are: 1) the target of the monoclonal antibody
and its specificity, 2) payload and its individual cytotoxic
potency, 3) the linker technology which will vary depend-
ing on the type of payload.
The linker technology was selected for maximum
stability of the loaded antibody. In the present study we
chose to have an assessment of target expression using
FZD10-imaging with an 111In-labeled version of
OTSA-101. Our study aimed to evaluate the in vivo
111In-OTSA-101 biodistribution and tumors biding ra-
ther than evaluating the maximal tolerated dose. As this
was our main aim, we did not organize our study as a
real 3 + 3 dose escalating study. Once biodistribution
and tumors uptake would have been considered compat-
ible with treatment, patients would be randomized to
receive different doses of 90Y-OTSA-101, to give them
more chance to receive an efficient dose. In standard
dose escalation studies, as most responses occur be-
tween 80 and 120% of the Maximum Tolerated Dose
(MTD), the first cohorts of patients are often treated
with low sub-therapeutic dose and only few patients
actually receive doses at or near the recommended
therapeutic dose. Patients would rather beneficiate from
a randomized study, giving more chance to patients to
receive the effective dose treatment.
In the imaging part, we observed significant
intra-patient and inter-patient differences in uptake in-
tensity and uptake rates. Indeed, some patients had very
low or no significant uptake of 111InOTSA-101 while in
some patients we observed rapid uptake of target le-
sions. Although this heterogeneity was anticipated based
on the preclinical data used as a basis for this study (8 of
Table 4 Best overall tumor response
Tumor Response
as per RECIST v1.1
Arm A, N = 3 Arm B, N = 5





CR complete response, PR partial response, SD stable disease, PD progressive
disease as per RECIST 1.1
Fig. 5 Response to treatment assessed for each patient on time to disease progression in weeks after 90Y-OTSA-101 injection
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13 SS patients had overexpression of FZD10, 4/13 had
detectable expression and one patient had no detectable
FZD10 in the initial study by Nagayama et al. [3]), its
importance was underestimated. The precise molecular
or pharmacological mechanisms for these differences
have not been explored in the current study. Another
hurdle encountered during the preparation and conduct
of this study, was the lack of validated immunohisto-
chemistry (IHC) assay to assess FZD10 expression on
tumor cells. This lead us to propose the imaging part of
the study as a biomarker, with the aim of reducing the
number of patients exposed to Yttrium 90 to those most
likely to benefit due to high in vivo expression. Due to
the lack of available data at the time the study was initi-
ated, we chose an arbitrary threshold of uptake based on
a visual assessment of tumor uptake compared to back-
ground following Krenning’s grades applied for peptide
receptors radionuclide therapy (PRRT) of endocrine tu-
mors [14]. This visual scale allows for patients selection
for PRRT as higher objective responses leading to longer
survival and improved quality of life have been observed
in case of higher grade tumors uptake [15]. Molecular
imaging allows for a non-invasive whole body in vivo
characterisation of the heterogeneity of tumors antigen
or receptors expression between primary and metastases
and as well as between metastases, supplementing the
traditional role of using imaging for localizing and
measuring disease. For example, it is currently used to
conduct treatment of endocrine tumors as somatostatin
receptors scintigraphy and 18F-FDG PET/CT are able to
quantify sites of well and poorly differentiated disease,
respectively, and therefore to treat more aggressively
18F-FDG PET/CT positive endocrine tumors [16].
Indeed, these whole body images are less influenced by
biopsy bias. The in vivo expression of FZD10 was not
assessed on tumor biopsy as this procedure is exposed
to sampling error and may not reflect the entire tumor
cells heterogeneity. This is bypassed by whole body scin-
tigraphies that allow tracking the radiotracer in the en-
tire body and in every tumor. This is how we observed
the difference of radiotracer uptake from one lesion to
another and how we can proceed to dosimetry studies.
Changes in radiotracers compounds can influence and
change the biodistribution. This is the way we can
improve the way they target tumors rather than normal
tissues and thereafter, based on dosimetry studies, select
the best molecule. This is the basis of theranostic in nu-
clear medicine [17, 18].
Kinetic of the lesions uptake reached maximum inten-
sity as soon as 1 h post-injection in some patients while it
would become obvious only on the latest acquisitions in
others, consistent with specific tumor suptake. The tu-
mors radiotracer retention observed confirmed radiotracer
internalization. Some bulky tumors demonstrated hetero-
geneous tracer uptake as a result of the various tumors
vascularizations, tumor necrosis depending on tumor size,
the capacity of the antibody to diffuse into the tumors, the
expression of FZD10, the antibody internalization. Thus,
bystander effect or even the abscopal effect of radiophar-
maceutical may occur only on a portion of the viable cells
that would not show tracer uptake.
Tracer kinetic depends on tumors vascularization but
also on tracer size. Antibodies are large molecules
known to have poor tissues penetration and long circu-
lating half-life. For this reason, more recent radionuclide
therapy trials favour smaller radiolabelled vectors than
antibody, such as fragments of antibodies (FAb), or
mostly peptides, displaying more rapid tissue distribu-
tion and faster blood clearance, leading to almost no
toxicity [19, 20]. Therefore, the development of FAb tar-
geting FZD10 may improve radiotracer kinetic and le-
sions uptake and reduce toxicity. It could be also
possible to radiolabel it with a long physical half-life
positron emitter such as Zirconium-89 (78.4 h) rather
than Indium-111 to increase radiotracer detection in
tumors by using Positron Emission Tomography (PET)
camera, known for a better resolution than SPECT.
Overall loaded 90Y-OTSA-101 was well tolerated at all
dose levels and no formal MTD was determined. No
significant drug-related AE was observed with
111In-OTSA-101 but the injected doses were low in part 1
of the study to limit receptor occupancy by
non-therapeutic antibody. In the second part of the study,
the most common AEs were cytopenia and fatigue, with
Table 5 Phamacokinetics results for imaging part (A) and
therapeutic part (B)
Parameter Cmax Tmax T1/2 AUC C0-336a CL Vdss
Units ng/mL Hours Hours ng*Hours/mL mL/Hours mL
A. Imaging Part (n = 17)
Mean 483.8 1.3 265.7 154,724 38.6 3311.9
S.D. 193.3 2.2 316.9 378,371 15.9 998.3
%CV 39.9 167.9 119.3 244.55 41.3 30.3
B. Therapeutic part (n = 8)
ARM A (370 MBq, n = 3)
Mean 365.4 0.00 87.4 42,106.7 255.4 4950.0
S.D. 240.3 66.6 38,489.5 391.9 4811.6
%CV 65.7 76.2 91.41 153.5 97.2
ARM B (1100 MBq, n = 4b)
Mean 362.0 1.0 61.8 38,275.0 63.0 1787.7
S.D. 112.2 1.1 29.0 15,024.7 46.1 1040.5
%CV 31.0 115.5 46.9 39.25 73.1 58.2
NB: PK data were not analyzed for patients ID 01–0018, 01–019, 01–020 due to
premature study and OTS-France closure
aor AUC extrapolated and BLQ concentration set to zero. bdata following the
2nd injection of patient 01–003 are included
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thrombocytopenia being the more problematic. Bone
marrow suppression, which results in cytopenia, is most
likely due to the exposure of the bone marrow to 90Y ei-
ther bound to OTSA-101 during blood perfusion of bone
marrow, or free 90Y which tends to accumulate in the
bone marrow. Other isotopes such as Lutetium 177
(177Lu) for example are associated with reduced bone mar-
row suppression compared to 90Y [21, 22], due to a
shorter mean pathway of less energetic electrons emitted
(12 mm mean pathway in the water and Maximum 2270
Kev for 90Y vs 1.5 mm and 497 Kev for 177Lu).
We performed 2D dosimetry on 111In-OTSA-101
whole body acquisitions to estimate the absorbed dose
of normal organs (liver, spleen, kidneys) when the pa-
tient would be treated with either 370 or 1110 MBq of
90Y-OTSA-101. As usually observed in RIT, liver was the
most targeted normal organ by the radiolabeled anti-
body. However, the mean absorbed liver dose was calcu-
lated after Indium 111 in order to prevent reaching the
20 Gy Maximal Tolerated Dose (MTD) limit applied to
external beam radiotherapy. When looking at liver tox-
icity, only one grade 1 bilirubin increase was reported in
one patient treated by the lowest activity, contrasting
with systematic bone marrow toxicity despite low visual
bone marrow uptake and no diffuse medullary metasta-
ses in any patient. We recently reported the results of a
3D dosimetry based on Montecarlo simulations
performed on these patients [23]. The calculated
absorbed doses in the liver would range from 4.3 to
13 Gy, consistent with the 2D dosimetry results and the
absence of liver toxicity. On the other hand, the
absorbed dose in the bone marrow would be greater
than 1.8 Gy for 5 patients, which is close to the MTD
estimated around 2 Gy, partially explaining the observed
bone marrow toxicity.
Efficacy of 90Y-OTSA-101 on tumors was mostly tran-
sient stabilized disease until disease progression. Most of
the patients included in this phase I trial presented with
bulky lung metastases. For this reason, a highly energetic
electrons emitter such as 90Y would be more suitable to
treat these lesions. However, these lesions were rapidly
growing while radionuclide therapies demonstrate
delayed response to treatment. This is well known for
slowly progressive disease such as neuroendocrine tu-
mors or thyroid cancers, with non-bulky disease. More-
over, the highly heterogeneous and mostly low
111In-OTSA-101 uptake observed in these tumors would
lead to low absorbed doses in the tumors partially
explaining the lack of treatment response especially in
bulky tumors.
Altogether, when using 177Lu radiolabelled small mole-
cules radionuclide therapy tend to be less toxic allowing
increased injected doses in order to increase absorbed
tumors doses. As a recent example, PSMA was first
targeted with antibodies (J591) for diagnosis and
therapeutic purpose of prostate adenocarcinoma. The
maximum tolerated dose (MTD) due to marrow toxicity
was 4 times lower when using 90Y-J591 than with
177Lu-J591 [22, 24]. For the past few years, high radiola-
beled PSMA avid small molecules have been developed
and used with great success for diagnosis and treatment.
Different types of 177Lu-PSMA appeared to be highly
tolerated with administered activities being twice the
MTD of 177Lu-J591 with almost no grade 3–4 hemato-
toxicity in these populations of heavily pre-treated
patients with bone metastases [19, 25, 26]. Moreover,
dosimetry studies evaluate the absorbed tumors dose
sometimes exceeding 100 Gy due to intense
homogenous target lesions tracer uptake, which is far
above the 10 Gy maximal absorbed dose in tumors we
estimated on 3D [23].
Conclusions
We confirmed the in vivo capacity of a new radiolabeled
antigen targeting FZD10 to get trapped in at least one
metastasis in 20 patients presenting with metastatic syn-
ovial sarcoma. However, the 111In-OTSA-101 tumors
uptake appeared highly heterogeneous and was consid-
ered intense enough to select patients for 90Y-OTSA-101
treatment in only half of the 20 patients included. A
theranostic approach appeared feasible in a first in
human phase I study in a very rare cancer using a
national networking. Transient stable disease was
observed in 5 of the 8 treated patients. However, as most
of the patients presented significant hematotoxicity re-
lated to treatment, the use of small fragments of anti-
bodies targeting FZD10 radiolabeled with lower
energetic electron emitter such as Lutetium 177 would
be a favored option for further development.
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